-
Psychometric Evaluation of the Impact of Weight on Quality of Life–Lite Clinical Trials (IWQOL-Lite-CT) Version in Adults Participating in a Pharmacological Clinical Trial for Obesity
Sep 9, 2025, 16:22 PM -
Population-Level Impact of Emicizumab in Algeria: A 25-Year Projection
Sep 9, 2025, 16:22 PM -
Adherence to Guidelines for the Treatment of Diabetes With Modern Antidiabetic Drugs in the Czech Republic: Clinical and Economic Impacts
Sep 9, 2025, 16:22 PM -
Navigating Three Systems: A Comparative Analysis of Pharmaceutical Reimbursement in Germany, Austria, and Switzerland
Sep 9, 2025, 16:22 PM -
Evolution of Utilization and Costs of Long-Acting Injectable Antipsychotics (LAIs) in Outpatient Care at Lisbon Psychiatric Hospital (March-May 2022 vs. 2025)
Sep 9, 2025, 16:22 PM -
Development and Validation of an Automated Cancer Stage Classifier for Real-World Oncology Data Mapped to the OMOP Common Data Model
Sep 9, 2025, 16:22 PM -
A Real-World Retrospective Study on the Utilization of Antifibrotic Drugs in Greece During the Period 2019-2023
Sep 9, 2025, 16:22 PM -
English Translation, Cross-Cultural Adaptation and Validation of the French New Patient-Reported Outcome Measures of the Multiple Sclerosis Autonomy Scale (MSAS)
Sep 9, 2025, 16:22 PM -
Evaluating the Impact of Different Payment Models on the Cost-Effectiveness and Budget Impact of Cell and Gene Therapies: Eladocagene Exuparvovec As a Case Study
Sep 9, 2025, 16:22 PM -
Psychotropic Medications to Patients With Treatment-Resistant Depression in France
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of Ondansetron Oral Dissolving Film vs. Oral Solution in the Chemotherapy-Induced Nausea and Vomiting for Egyptian Pediatric Patients
Sep 9, 2025, 16:22 PM -
Sex Differences in Characteristics and Treatment Patterns of Patients With Sleep Disorders in South Korea
Sep 9, 2025, 16:22 PM -
Societal Burden of Specific Learning Disorders With Focus on Secondary Mental Health Problems in Japan
Sep 9, 2025, 16:22 PM -
Reassessment of Orphan Drugs in Germany After Exceeding the Annual Sales Limit of €30 Million: Impact on the Reimbursement Price and Key Influencing Factors
Sep 9, 2025, 16:22 PM -
Bigger, Better Studies: Prioritizing Literature Review Using an Approach Based on Large Language Models
Sep 9, 2025, 16:22 PM -
Understanding the Consequences of International Reference Pricing on Cancer Immunotherapy in Europe: A 10-Year Price Corridor Analysis
Sep 9, 2025, 16:22 PM -
Are We SEEing It Yet? The Use of Structured Expert Elicitation Protocols for Decision Making
Sep 9, 2025, 16:22 PM -
Identifying Patient-Reported Outcome Measures to Capture Patients’ Experiences of Symptoms and Impacts of Acute Myeloid Leukemia (AML)
Sep 9, 2025, 16:22 PM -
Utility Values From Pooled Analysis of High Concentration (179 mg) Capsaicin Patch (HCCP) Studies In Peripheral Neuropathic Pain (PNP)
Sep 9, 2025, 16:22 PM -
Resource Utilization Among Patients With Epidermolysis Bullosa: Preliminary Findings From Seven European Countries
Sep 9, 2025, 16:22 PM
